Market Summary
USD172.17-0.04
Market Closed-0.02%
RETA Alerts
RETA Stock Price
RETA RSI Chart
RETA Valuation
RETA Price/Sales (Trailing)
RETA Profitability
RETA Fundamentals
RETA Revenue
RETA Earnings
Price Action
52 Week Range
172.21
(Low)(High)
Last 7 days
0.1%
Last 30 days
1.8%
Last 90 days
77.3%
Trailing 12 Months
544.3%
RETA Financial Health
RETA Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for RETA
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-14 | Loewen Andrea | sold | -546,181 | 172 | -3,175 | svp, global regulatory affairs |
2023-09-05 | Anand Bhaskar | sold | -68,695 | 169 | -406 | svp, chief accounting officer |
2023-08-23 | ROSE WILLIAM | gifted | - | - | -500,000 | - |
2023-08-16 | WORTLEY MICHAEL D | sold | -67,166 | 168 | -398 | chief legal officer |
2023-08-16 | Soni Manmeet Singh | sold | -295,566 | 168 | -1,755 | coo, cfo and president |
2023-08-16 | Anand Bhaskar | sold | -35,367 | 168 | -210 | svp, chief accounting officer |
2023-08-16 | Bir Dawn Carter | sold | -66,996 | 168 | -398 | chief commercial officer |
2023-08-16 | Meyer Colin John | sold | -100,569 | 168 | -596 | chief innovation officer |
2023-08-15 | WORTLEY MICHAEL D | sold | -136,415 | 169 | -807 | chief legal officer |
2023-08-15 | Meyer Colin John | sold | -362,483 | 169 | -2,144 | chief innovation officer |
Which funds bought or sold RETA recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-06 | Deep Track Capital, LP | sold off | -100 | -66,280,700 | - | -% |
2023-08-24 | PERCEPTIVE ADVISORS LLC | reduced | -69.1 | -128,896,000 | 68,334,200 | 1.98% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -34.62 | -200,519 | 551,118 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -9.67 | 39,996 | 3,129,460 | -% |
2023-08-21 | BOKF, NA | sold off | -100 | -2,273 | - | -% |
2023-08-21 | VisionPoint Advisory Group, LLC | new | - | 41,090 | 41,090 | 0.02% |
2023-08-21 | Affinity Asset Advisors, LLC | new | - | 2,967,550 | 2,967,550 | 1.04% |
2023-08-17 | Orion Portfolio Solutions, LLC | added | 0.19 | 30,064 | 273,457 | -% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -15.37 | -514,784 | 9,588,220 | -% |
2023-08-16 | GTS SECURITIES LLC | new | - | 798,653 | 798,653 | 0.03% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
RETA Alerts
Schedule 13G FIlings of Reata Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Sep 19, 2023 | rose william | 8.9% | 3,182,950 | SC 13D/A | |
| Aug 24, 2023 | rose william | 9.1% | 3,240,950 | SC 13D/A | |
| Aug 07, 2023 | biogen inc. | 23.4% | 8,936,791 | SC 13D | |
| Aug 01, 2023 | cpmg inc | 13.2% | 4,589,758 | SC 13D/A | |
| Jul 31, 2023 | rose william | 9.2% | 3,240,950 | SC 13D/A | |
| Jun 26, 2023 | adage capital partners gp, l.l.c. | 5.24% | 1,730,841 | SC 13G | |
| May 15, 2023 | first light asset management, llc | 3.91% | 1,290,193 | SC 13G/A | |
| Mar 07, 2023 | perceptive advisors llc | 6.5% | 2,083,799 | SC 13G | |
| Feb 14, 2023 | first light asset management, llc | 6.79% | 2,155,552 | SC 13G/A | |
| Feb 14, 2023 | point72 asset management, l.p. | 0% | 0 | SC 13G/A |
Recent SEC filings of Reata Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 19, 2023 | SC 13D/A | 13D - Major Acquisition | |
| Sep 18, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 12, 2023 | 8-K | Current Report | |
| Sep 12, 2023 | DEFA14A | DEFA14A | |
| Sep 07, 2023 | 4 | Insider Trading | |
| Sep 05, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 05, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 24, 2023 | 4 | Insider Trading |
Peers (Alternatives to Reata Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 512.5B | 29.5B | 3.56% | 89.32% | 78.88 | 17.36 | 1.53% | 14.16% |
JNJ | 423.3B | 97.8B | -2.65% | 0.10% | 32.43 | 4.33 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -2.13% | 26.48% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 189.8B | 77.9B | -9.16% | -24.26% | 8.84 | 2.44 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -5.06% | -15.06% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.75% | 544.26% | -74.04 | 4.1K | -86.94% | 71.24% |
PRGO | 4.5B | 4.6B | -11.49% | -16.32% | -66.69 | 0.98 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
TLRY | 1.9B | 627.1M | -7.75% | -1.79% | -1.34 | 3.1 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -11.88% | -19.94% | 34.62 | 2.37 | 0.62% | -24.59% |
INVA | 832.3M | 244.3M | -4.13% | 4.68% | 4.22 | 3.41 | -39.50% | -4.99% |
CRON | 830.8M | 109.5M | 21.79% | -27.57% | -5.79 | 7.59 | -2.66% | -32.13% |
CGC | 480.0M | 453.3M | 110.37% | -71.69% | -0.39 | 1.06 | -16.04% | 55.90% |
ACRS | 479.1M | 31.2M | -7.77% | -52.62% | -4.55 | 15.37 | 407.54% | -26.47% |
OCUL | 269.4M | 54.6M | -13.04% | -44.44% | -2.97 | 4.93 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
Reata Pharmaceuticals News
Returns for RETA
Cumulative Returns on RETA
29.8%
7-Year Cumulative Returns
14.5%
5-Year Cumulative Returns
17.8%
3-Year Cumulative Returns
Risks for RETA
What is the probability of a big loss on RETA?
100%
Probability that Reata Pharmaceuticals stock will be more than 20% underwater in next one year
86.5%
Probability that Reata Pharmaceuticals stock will be more than 30% underwater in next one year.
82.7%
Probability that Reata Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does RETA drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Reata Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Financials for Reata Pharmaceuticals
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | - | - | - | 2,216,000 | 3,149,000 | 10,000,000 | 11,459,000 | 11,490,000 | 13,748,000 | 7,758,000 | 8,610,000 | 9,019,000 | 8,499,000 | 15,340,000 | 20,100,000 | 26,517,000 | 32,296,000 | 29,229,000 | 28,967,000 | 53,589,000 | 55,101,000 | 62,483,000 |
| Operating Expenses | 15.4% | 376,149,000 | 325,947,000 | 280,250,000 | 273,228,000 | 267,687,000 | 265,291,000 | 256,198,000 | 240,868,000 | 231,168,000 | 222,484,000 | 235,344,000 | 365,274,000 | 356,308,000 | 344,133,000 | 311,737,000 | 158,007,000 | 145,922,000 | 138,653,000 | 130,467,000 | 123,583,000 | 113,423,000 |
| S&GA Expenses | 14.7% | 159,868,000 | 139,321,000 | 109,277,000 | 107,816,000 | 106,282,000 | 103,137,000 | 99,002,000 | 87,865,000 | 80,443,000 | 75,045,000 | 75,128,000 | 77,972,000 | 73,941,000 | 69,047,000 | 58,298,000 | 43,973,000 | 37,176,000 | 36,159,000 | 32,748,000 | 30,751,000 | 29,416,000 |
| R&D Expenses | 9.6% | 203,305,000 | 185,516,000 | 169,843,000 | 164,236,000 | 160,181,000 | 160,916,000 | 155,993,000 | 151,836,000 | 149,589,000 | 146,306,000 | 159,080,000 | 161,780,000 | 156,876,000 | 149,647,000 | 128,109,000 | 113,256,000 | 108,121,000 | 101,996,000 | 97,288,000 | 92,423,000 | 83,605,000 |
| EBITDA | 100.0% | - | -353,122,000 | -310,796,000 | - | -303,155,000 | -298,089,000 | -290,070,000 | -270,396,000 | -264,294,000 | -255,455,000 | -255,010,000 | -373,790,000 | -347,179,000 | -317,186,000 | -278,631,000 | -118,804,000 | -110,003,000 | -105,358,000 | -74,010,000 | -67,022,000 | -50,386,000 |
| EBITDA Margin | 100.0% | - | -235 | -140 | - | -30.32 | -26.01 | -25.25 | -19.67 | -34.07 | -29.67 | -28.27 | -43.98 | -22.63 | -15.78 | -10.51 | -3.68 | -3.76 | -3.64 | -1.38 | -1.22 | -0.81 |
| Interest Expenses | - | 2,624,000 | - | - | - | - | - | - | - | - | 4,847,000 | 8,021,000 | 10,002,000 | 12,391,000 | 9,957,000 | 8,207,000 | 7,822,000 | 7,793,000 | 6,283,000 | 4,741,000 | 3,980,000 | 2,104,000 |
| Earnings Before Taxes | 75.2% | -87,678,000 | -354,232,000 | -311,926,000 | -311,535,000 | -304,379,000 | -304,176,000 | -297,836,000 | -278,596,000 | -272,299,000 | -266,530,000 | -270,239,000 | -391,306,000 | -365,413,000 | -332,189,000 | -290,162,000 | -128,740,000 | -119,910,000 | -113,755,000 | -80,520,000 | -71,626,000 | -53,107,000 |
| EBT Margin | 100.0% | - | -236 | -140 | -98.93 | -30.44 | -26.54 | -25.92 | -20.26 | -35.10 | -30.96 | -29.96 | -46.04 | -23.82 | -16.53 | -10.94 | -3.99 | -4.10 | -3.93 | -1.50 | -1.30 | -0.85 |
| Net Income | 75.3% | -87,623,000 | -354,176,000 | -311,901,000 | -311,784,000 | -304,628,000 | -303,773,000 | -297,386,000 | -277,777,000 | -271,387,000 | -266,268,000 | -247,752,000 | -368,918,000 | -343,156,000 | -309,955,000 | -290,170,000 | -128,810,000 | -119,951,000 | -113,782,000 | -80,546,000 | -71,638,000 | -53,111,000 |
| Net Income Margin | 100.0% | - | -236 | -140 | -99.01 | -30.46 | -26.51 | -25.88 | -20.20 | -34.98 | -30.93 | -27.47 | -43.41 | -22.37 | -15.42 | -10.94 | -3.99 | -4.10 | -3.93 | -1.50 | -1.30 | -0.85 |
| Free Cashflow | 100.0% | - | -230,654,000 | -207,537,000 | -279,869,000 | -275,826,000 | -250,299,000 | -237,030,000 | -159,433,000 | -156,849,000 | -327,213,000 | -323,267,000 | -427,367,000 | -427,782,000 | -265,190,000 | -253,824,000 | -142,002,000 | -98,299,000 | -90,182,000 | -84,462,000 | -71,525,000 | -93,747,000 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 10.8% | 503 | 454 | 514 | 584 | 632 | 680 | 735 | 732 | 778 | 815 | 858 | 613 | 652 | 664 | 682 | 259 | 300 | 331 | 345 | 382 | 175 |
| Current Assets | 20.8% | 402 | 333 | 398 | 445 | 491 | 537 | 596 | 722 | 768 | 806 | 847 | 607 | 640 | 652 | 669 | 247 | 287 | 317 | 342 | 380 | 172 |
| Cash Equivalents | -42.5% | 49.00 | 85.00 | 42.00 | 32.00 | 147 | 532 | 590 | 713 | 756 | 778 | 818 | 578 | 610 | 624 | 664 | 240 | 280 | 313 | 338 | 375 | 139 |
| Inventory | - | 3.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net PPE | 2.2% | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 12.00 | 7.00 | 6.00 | 5.00 | 5.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 1.00 | 1.00 | 1.00 |
| Current Liabilities | 129.1% | 125 | 55.00 | 59.00 | 51.00 | 46.00 | 44.00 | 54.00 | 121 | 121 | 114 | 119 | 47.00 | 47.00 | 201 | 192 | 75.00 | 68.00 | 61.00 | 56.00 | 63.00 | 56.00 |
| Long Term Debt | - | 73.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 80.00 | 80.00 | 79.00 | 79.00 | 79.00 |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 156 | 155 | 75.00 | - | - | 79.00 | - | - |
| Shareholder's Equity | 166.8% | 87.00 | -130 | -65.69 | 5.00 | 69.00 | 128 | 186 | 256 | 314 | 369 | 417 | 186 | 232 | 229 | 257 | - | - | - | 15.00 | 38.00 | - |
| Retained Earnings | 11.5% | -1,490 | -1,683 | -1,567 | -1,482 | -1,403 | -1,329 | -1,255 | -1,170 | -1,098 | -1,025 | -958 | -892 | -827 | -759 | -710 | -523 | -483 | -449 | -420 | -394 | -363 |
| Additional Paid-In Capital | 1.6% | 1,578 | 1,553 | 1,502 | 1,487 | 1,472 | 1,457 | 1,442 | 1,426 | 1,412 | 1,395 | 1,376 | 1,078 | 1,059 | 988 | 967 | 456 | 450 | 445 | 435 | 432 | 196 |
| Shares Outstanding | 2.0% | 38.00 | 37.00 | - | 37.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 34.00 | 34.00 | 33.00 | 33.00 | 30.00 | 30.00 | 30.00 | 30.00 | 28.00 | 27.00 | 26.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -9.1% | -248,337 | -227,531 | -204,267 | -276,773 | -272,397 | -248,875 | -235,701 | -157,909 | -155,844 | -326,178 | -322,340 | -426,575 | -426,817 | -263,592 | -251,151 | -139,273 | -95,796 | -88,494 | -83,783 | -71,019 | -93,192 |
| Share Based Compensation | 8.0% | 87,843 | 81,344 | 58,731 | 58,980 | 58,191 | 57,571 | 56,806 | 53,529 | 51,452 | 53,005 | 57,633 | 57,975 | 51,775 | 41,461 | 26,381 | 16,857 | 14,223 | 12,292 | 10,550 | 9,583 | 8,382 |
| Cashflow From Investing | 125.4% | 59,417 | -233,881 | -345,164 | -405,863 | -337,399 | -1,424 | -1,329 | -1,524 | -1,005 | -1,035 | -927 | -792 | -965 | -1,598 | -2,673 | -2,729 | -2,503 | -1,688 | -679 | -505 | -554 |
| Cashflow From Financing | 530.4% | 90,609 | 14,373 | 1,485 | 1,342 | 1,243 | 4,654 | 9,138 | 294,382 | 302,137 | 480,349 | 477,093 | 765,481 | 757,752 | 576,622 | 580,358 | 6,966 | 240,072 | 297,301 | 292,472 | 292,109 | 167,246 |
RETA Income Statement
2023-06-30Unaudited Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues | ||||
| Total revenues | $ 22,746 | $ 762 | $ 22,941 | $ 1,677 |
| Operating cost and expenses | ||||
| Cost of products sold | 846 | 0 | 846 | 0 |
| Research and development | 57,120 | 39,331 | 112,597 | 79,136 |
| Selling, general and administrative | 45,690 | 25,143 | 100,575 | 49,984 |
| Litigation settlement | 11,000 | 11,000 | ||
| Depreciation | 293 | 273 | 581 | 581 |
| Total operating cost and expenses | 114,949 | 64,747 | 225,599 | 129,701 |
| Other income (expense), net | 285,201 | (9,571) | 279,539 | (19,343) |
| Income (loss) from operations | 192,998 | (73,556) | 76,881 | (147,367) |
| Benefit from (provision for) taxes on income | 0 | 1 | 0 | (30) |
| Net income (loss) | $ 192,998 | $ (73,555) | $ 76,881 | $ (147,397) |
| Net income (loss) per share - basic | $ 5.12 | $ (2.02) | $ 2.06 | $ (4.04) |
| Net income (loss) per share - diluted | $ 4.65 | $ (2.02) | $ 1.89 | $ (4.04) |
| Weighted-average number of common shares used in net income (loss) per share - basic | 37,671,678 | 36,467,802 | 37,311,872 | 36,440,364 |
| Weighted-average number of common shares used in net income (loss) per share - diluted | 41,506,900 | 36,467,802 | 40,758,929 | 36,440,364 |
| Product revenues, net | ||||
| Revenues | ||||
| Total revenues | $ 20,038 | $ 0 | $ 20,038 | $ 0 |
| License and milestone | ||||
| Revenues | ||||
| Total revenues | 0 | 754 | 0 | 1,648 |
| Other revenue | ||||
| Revenues | ||||
| Total revenues | $ 2,708 | $ 8 | $ 2,903 | $ 29 |
RETA Balance Sheet
2023-06-30Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Assets | ||
| Cash and cash equivalents | $ 48,843 | $ 42,312 |
| Marketable debt securities | 281,371 | 345,202 |
| Accounts receivable, net | 22,662 | 0 |
| Prepaid expenses and other current assets | 46,031 | 10,256 |
| Inventory, current | 2,942 | 0 |
| Total current assets | 401,849 | 397,770 |
| Property and equipment, net | 11,303 | 11,179 |
| Operating lease right-of-use-assets | 78,598 | 105,258 |
| Inventory, noncurrent | 10,338 | 0 |
| Other assets | 499 | 284 |
| Total assets | 502,587 | 514,491 |
| Liabilities and stockholders' equity (deficit) | ||
| Accounts payable | 19,860 | 18,706 |
| Accrued direct research liabilities | 25,135 | 13,836 |
| Other current liabilities | 71,991 | 24,267 |
| Liability related to sale of future royalties, current | 5,650 | 0 |
| Operating lease liabilities, current | 2,456 | 2,151 |
| Total current liabilities | 125,093 | 58,960 |
| Opearting lease liabilities, noncurrent | 90,417 | 117,313 |
| Term Loan, net of debt issuance cost | 73,130 | 0 |
| Liability related to sale of future royalties, non-current | 126,656 | 403,913 |
| Total noncurrent liabilities | 290,203 | 521,226 |
| Commitments and contingencies | ||
| Stockholders' equity (deficit): | ||
| Additional paid-in capital | 1,577,904 | 1,501,800 |
| Accumulated deficit | (1,490,651) | (1,567,532) |
| Total stockholders' equity (deficit) | 87,291 | (65,695) |
| Total liabilities and stockholders' equity (deficit) | 502,587 | 514,491 |
| Common Stock A | ||
| Stockholders' equity (deficit): | ||
| Common stock value | 33 | 32 |
| Common Stock B | ||
| Stockholders' equity (deficit): | ||
| Common stock value | $ 5 | $ 5 |
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.